002424 Guizhou Bailing Group Pharmaceutical
- 5.00
- -0.26-4.94%
Guizhou Bailing Group Pharmaceutical News
ST Bering (002424.SZ): Accumulated cost of 84.62 million yuan to buy back 0.83% of shares
Glonghui, May 7 | ST Bering (002424.SZ) announced that as of April 30, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 11,668,812 shares, accounting for 0.83% of the company's current total share capital. The highest transaction price was 8.22 yuan/share, the minimum transaction price was 6.59 yuan/share, and the total transaction amount was 84,620,058.20 yuan (excluding transaction fees).
In-depth marketing model reform promotes Guizhou Bailing's revenue exceeding 4.2 billion yuan in 2023
Guizhou Bailing is playing a series of combo punches such as “marketing system reform, capacity expansion technology reform, product release, and new drug research and development.” In particular, after comprehensively advancing the marketing model reform, the company went to battle lightly, actively embraced change, and cultivated new quality productivity, and had saved up energy for the next development cycle.
Guizhou Bailing (002424.SZ) announced first-quarter results, net profit of 51.6951 million yuan, a decrease of 44.00%
According to the Zhitong Finance App, Guizhou Bailing (002424.SZ) released its report for the first quarter of 2024. The company's revenue was 1,333 billion yuan, an increase of 22.09% over the previous year. Net profit attributable to shareholders of listed companies was RMB 51.6951 million, a year-on-year decrease of 44.00%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 44.6057 million yuan, a year-on-year decrease of 49.57%. Basic earnings per share were $0.04.
Guizhou Bailing (002424.SZ) was approved as the first grade 2 protected variety of traditional Chinese medicine
Guizhou Bailing (002424.SZ) announced, recently, the China Drug Administration (“State Drug Administration”)...
Five listed companies including Jingu Co., Ltd. announced the chairman's proposal to repurchase shares after the market
Gelonghui, April 17 | According to incomplete statistics, five A-share listed companies, including Yongan Bank, Huifa Foods, Guangfeng Technology, Jingu Co., Ltd., and Minde Electronics announced that their chairmen proposed to repurchase shares after the market. In addition, Guizhou Bailing plans to change the use of some of the shares that have already been repurchased. The use of the repurchased shares will be changed from “for employee stock ownership plans or equity incentives” to “for cancellation and corresponding reduction of registered capital.” Jiang Han New Materials plans to raise the maximum share repurchase price from no more than 23.5 yuan/share to no more than 25 yuan/share.
Guizhou Bailing (002424.SZ): Accumulated cost of 84.621 million yuan to buy back 0.83% of shares
Gelonghui, March 4, 丨 Guizhou Bailing (002424.SZ) announced that as of February 29, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 11,668,812 shares, accounting for 0.83% of the company's current total share capital. The highest transaction price was 8.22 yuan/share, the minimum transaction price was 6.59 yuan/share, and the total transaction amount was 84.621 million yuan (excluding transaction fees).
Express News | Recently, wildfires have occurred in many parts of Guizhou. Local listed companies responded that there was no impact on the cultivation and procurement of Chinese herbal medicines
Express News | There have been frequent wildfires in many parts of Guizhou recently, and many local listed pharmaceutical companies have responded: there is no impact on the supply of medicinal herbs
Guizhou Bailing (002424.SZ): “Multi-center clinical research and mechanism discussion on the prevention of diabetes and retinal complications with the Miao Drug Tangning Tongluo Tablets” passed the acceptance
<国家中医药管理局科技司关于2021年度中医药科学技术研究专项部分课题验收结果的通知>Gelonghui, February 19, Guizhou Bailing (002424.SZ) announced that the company (recently received the “Notice on Forwarding” from the Guizhou Provincial Administration of Traditional Chinese Medicine), according to the “Notice of the Science and Technology Department of the State Administration of Traditional Chinese Medicine on the Acceptance Results of the 2021 Traditional Chinese Medicine Science and Technology Research Special Topics” (China Traditional Chinese Medicine Science and Technology Letter [2024] No. 28), after expert review and combined with the completion of the assessment indicators, the company “Miaoyao Duangning” Tongluo tablets to prevent diabetes and vision
Guizhou Bailing (002424.SZ): Initial repurchase of 6.7036 million shares involving 45.6863 million yuan
Glonghui, Feb. 6 | Guizhou Bailing (002424.SZ) announced that on February 5, 2024, the company repurchased 670.3612 million shares of the company's shares through a dedicated securities account through centralized bidding, accounting for 0.48% of the company's total share capital; the highest transaction price for the initial share repurchase was 6.94 yuan/share, the minimum transaction price was 6.59 yuan/share, and the total amount of capital used was 456.8863 million yuan (excluding transaction fees).
Express News | Nearly 20 listed companies disclosed plans to repurchase or increase their holdings up to 100 million yuan after the market and announced the repurchases of Precision Measurement Electronics, Yiqiao Shenzhou, and Shunwang Technology for cancellation
Express News | Guizhou Bailing: Plans to repurchase shares with 100 million yuan to 200 million yuan
Bailing Group Pharma Gets Green Light for Clinical Trial of New Hepatitis B Drug
Guizhou Bailing Group Pharmaceutical (SHE:002424) has received ethical review approval for a clinical trial of Tifentex tablets in combination with Entecavir tablets for the treatment of chronic hepat
Guizhou Bailing (002424.SZ): Clinical study on the interaction between tifentai tablets and entecavir tablets obtained ethical review approval
Guizhou Bailing (002424.SZ) issued an announcement. Recently, the company received Beijing You'an Hospital affiliated to Capital Medical University...
Guizhou Bailing (002424.SZ): As of November 30, 2023, the total number of shareholders in the company is 101193
Gelonghui, December 22|Guizhou Bailing (002424.SZ) stated on the investor interactive platform that as of November 30, 2023, the total number of shareholders in the company was 101,193.
Guizhou Bailing (002424.SZ): Guizhou Securities Regulatory Bureau ordered the company to take corrective measures
Guizhou Bailing (002424.SZ) announced that the company received the Guizhou Securities Regulatory Bureau's “On Pharmaceuticals for Guizhou Bailing Enterprise Group...
The novel coronavirus drug concept of A-shares continues to strengthen, and the new pharmaceutical industry rises and stops by 20CM
Gelonghui, December 13 | Tuoxin Pharmaceutical rose 20CM, Senxuan Pharmaceutical on the Beijing Stock Exchange rose more than 20%, Guizhou Bailing hit a rise and fall, and Guangshengtang and Hendy Pharmaceuticals rose more than 10%. According to the news, on December 9, the US Centers for Disease Control and Prevention (CDC) included JN.1 separately in the COVID-19 proximity forecast (SARS-CoV-2 Nowcast) for the first time, saying that JN.1 is currently the fastest-growing COVID-19 variant in the US. As of the same date, the CDC estimates that JN.1 will account for 15-29% of the popular variants in the US, but by the end of October, it will only account for less than 0.1 of the US COVID-19 variants
Guizhou Bailing (002424.SZ): Chlorpheniramine maleate tablets passed a consistent evaluation of the quality and efficacy of generic drugs
Gelonghui on December 5 | Guizhou Bailing (002424.SZ) announced that recently, Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. received the “Notice of Approval of Supplemental Application for Drug Supplement” for chlorpheniramine maleate tablets approved and issued by the State Drug Administration. After review, the product passed the generic drug quality and efficacy consistency evaluation. Chlorpheniramine maleate tablets are antihistamines used to treat allergic rhinitis, colds, sinusitis, and allergic skin diseases such as urticaria, allergic drug rash or eczema, angioedema, and itchy skin caused by insect bites.
Guizhou Bailing (002424.SZ) plans to invest in a wholly-owned subsidiary in Hengqin New District of Zhuhai to enhance its comprehensive strength
Guizhou Bailing (002424.SZ) announced that according to business development needs, the company plans to be located in Hengqin, Zhuhai, Guangdong Province...
Guizhou Bailing (002424.SZ): Plans to establish Bailing Yuxiu (Zhuhai) Pharmaceutical for 20 million yuan
Gelonghui November 24丨Guizhou Bailing (002424.SZ) announced that according to business development needs, the company plans to invest 20 million yuan in monetary capital to establish a wholly-owned subsidiary “Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd.” (provisional name, subject to industrial and commercial registration). The establishment of a wholly-owned subsidiary is conducive to improving the company's industrial layout, better developing markets, and enhancing the company's drug research and development capabilities.
Analysis
Price Target
No Data
